Should I Buy IPX? IPX 2026 Analysis

Should You Buy Iperionx Ltd (IPX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

42.070

1 Day change

-0.33%

52 Week Range

61.450

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the provided data, Iperionx Ltd (IPX) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators suggest a bearish trend, there are no positive trading signals, and no recent news or catalysts to drive the stock higher. Given the lack of financial data and no clear positive momentum, it is better to hold off on investing in this stock at this time.

Technical Analysis

The MACD histogram is negative and expanding, indicating a bearish trend. The RSI is at 22.987, which is neutral but close to oversold territory. Moving averages are converging, suggesting indecision in the market. The stock is trading near its key support level (S1: 40.965), with resistance levels at R1: 50.966 and R2: 54.055.

Positive Catalysts

NULL identified. There is no recent news or significant insider/hedge fund activity to suggest a positive catalyst.

Neutral/Negative Catalysts

The MACD indicates a bearish trend, and the stock's historical pattern suggests a likelihood of further short-term declines (-1.09% in the next day, -3.11% in the next week).

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is provided.

2 Analyst Rating

Wall Street analysts forecast IPX stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 42.210

Low

Averages

High

Current: 42.210

Low

Averages

High

Spruce Point Capital

downgrade

AI Analysis

2025-11-12

Reason

Spruce Point Capital

Price Target

AI Analysis

2025-11-12

downgrade

Reason

Spruce Point Capital, in a research note, said that after conducting a forensic review of IperionX and its ambitions of becoming a vertically integrated producer of titanium powders and products, the firm believes that investor expectations are too high, and it faces significant challenges in commercial efforts that may not be fully reflected in its valuation. Spruce Point also expressed concerns with the accuracy of its financial reporting and says it does not believe the end markets to be attractive or that its highly promoted HAMR process is likely to "revolutionize" the industry. Based on the firm's analysis, Spruce Point advises investors to exercise caution because the shares may be significantly overvalued, with potential downside risk of 70% - 95% under certain scenarios. Reference Link

Roth Capital

Buy

maintain

$64 -> $74

2025-10-01

Reason

Roth Capital

Price Target

$64 -> $74

2025-10-01

maintain

Buy

Reason

Roth Capital raised the firm's price target on IperionX to $74 from $64 and keeps a Buy rating on the shares. The firm cites the company's FY25 results and the receipt of additional government funding as part of its existing $47.1M award, the analyst tells investors in a research note. Roth adds that its higher price target reflects lower future dilution assumptions and a higher multiple on 2029 EBITDA.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IPX

Unlock Now

IPX Should I Buy

IPX Should I Buy

Should You Buy Iperionx Ltd (IPX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch